Anti-Müllerian Hormone (AMH): Nursing Guide
Serum anti-Müllerian hormone reflects ovarian follicle pool size in reproductive-age women and supports IVF stimulation planning — but it does not predict pregnancy by itself, cannot diagnose PCOS alone, and must be interpreted with age, symptoms, and the reporting laboratory’s assay-specific reference interval.
Contents
Quick Facts
Key Takeaway
AMH estimates how many immature eggs remain in the ovaries and stays relatively stable across the menstrual cycle in many assays — but it cannot confirm egg quality, guarantee future pregnancy, or.
Specimen & Collection Details
Nurse quick-reference for collection prep that affects result quality.
Serum gel (preferred) or red-top
Per laboratory protocol — the reporting laboratory prefers serum gel
Serum (venous blood)
Typically about 1 mL serum after centrifugation (follow local lab minimum)
May be drawn any cycle day for many indications; follow ordering clinician and laboratory instructions for IVF or pediatric protocols
No special preparation is usually required
Serum per laboratory stability requirements — refrigerated or frozen transport per reporting laboratory policy
Often 1–3 days at reference laboratories; may be longer if send-out
Reproductive endocrine / fertility laboratory (often send-out immunoassay)
What is Anti-Müllerian Hormone (AMH)?
Anti-Müllerian Hormone (AMH) is a blood test that measures anti-Müllerian hormone (AMH) in serum. In females, granulosa cells surrounding ovarian follicles produce AMH; levels generally reflect ovarian reserve (remaining egg supply). In males, Sertoli cells produce AMH during development and childhood. AMH is also used in selected pediatric and oncology monitoring contexts per specialist protocols.
Overview
Nurses encounter AMH most often in fertility clinics, gynecology offices, and IVF pathways where teams assess ovarian reserve, plan gonadotropin stimulation, or evaluate irregular cycles and suspected polycystic ovary syndrome (PCOS). The test is a standard venipuncture serum sample with no routine fasting requirement standard clinical references.
Because immunoassays are not standardized internationally, AMH values from different laboratories or assay generations cannot be compared directly. obstetric guidelines advises that AMH supports ovarian reserve assessment in infertile women and stimulation protocol selection, but routine AMH testing should not be used to counsel women without infertility about future fertility potential. Nurses help safe care by confirming indication, documenting patient questions, and ensuring results return to the responsible clinician for contextual interpretation.
Before venipuncture, verify identity, indication, and whether recent fertility drugs or high-dose biotin could affect some assays per laboratory cautions. After results, do not tell patients they can or cannot become pregnant based on AMH alone — coordinate prescriber follow-up and supportive counseling, and escalate acute distress or unexpected pediatric results according to facility policy.
AMH Counseling and Emotional Safety
AMH is widely discussed in fertility culture but easily misinterpreted. A single value cannot prove future pregnancy, rule out pregnancy, or diagnose PCOS without clinical criteria. Assay methods differ between laboratories, so nurses must prevent patients from comparing results to non-comparable internet charts.
- Nurse or patient treating AMH as a definitive fertility verdict
- Routine screening ordered in young women without infertility contrary to obstetric guidelines guidance
- Rejected or hemolyzed specimen delaying time-sensitive IVF planning
- Pediatric AMH results for disorders of sex development without urgent specialist pathway
- Acute behavioral health crisis after low AMH counseling
Document: indication, collection details, interfering medications, patient teaching boundaries, pending result plan, and prescriber notifications.
What AMH Can and Cannot Tell You
This test can help identify:
- Estimated ovarian reserve (follicle pool) in context of age and assay reference interval
- Expected ovarian response context for IVF stimulation planning when ordered by specialists
- Supportive data for PCOS assessment when combined with clinical features
- Presence of testicular hormone production in selected pediatric evaluations
- Trend monitoring for some AMH-secreting ovarian tumors when ordered by oncology
This test cannot:
- Predict whether pregnancy will occur or guarantee IVF success
- Assess egg quality or replace ultrasound antral follicle counts when needed
- Diagnose PCOS, menopause, or infertility alone
- Predict exact time to menopause
- Be compared across different laboratory assay platforms
Pre-IVF AMH Collection Checks
Verify
Clarify before proceeding when:
- Order indication is unclear or appears to be routine screening without infertility diagnosis
- Wrong specimen type ordered (e.g., plasma instead of serum per lab policy)
- Patient received interfering fertility medications within laboratory exclusion window
- Pediatric AMH ordered without specialist pathway identified
- Patient expects immediate interpretation at bedside before prescriber review
- Prior AMH was performed on a different assay and direct comparison is requested without recollection
- Specimen hemolyzed on difficult draw — consider repeat per laboratory policy
AMH, Ovarian Reserve, and Pregnancy Expectations
Integrate AMH with age, clinical symptoms (cycle pattern, hirsutism, hot flashes), antral follicle count on ultrasound when available, prior AMH on the same assay, and treatment goals (IVF, expectant management, PCOS workup). Trends on one laboratory method matter more than comparing values between hospitals.
| Clinical context | Pair with AMH | Nursing focus |
|---|---|---|
| Pre-IVF planning | Ultrasound AFC, age, prior cycle response | Track pending results; avoid promising egg numbers; notify fertility team of delays |
| Suspected PCOS | Menstrual history, metabolic screening, exam | Do not label patient with PCOS based on AMH alone |
| Amenorrhea under age 40 | FSH, estradiol, pregnancy test if indicated | Support prompt endocrine follow-up for possible primary ovarian insufficiency |
| Pediatric DSD workup | Specialist orders, karyotype, imaging | Ensure expedited routing per pediatric endocrine protocol |
AMH Conversations and Emotional Safety at the Bedside
| Bedside point | Nursing note |
|---|---|
| No routine fasting | standard clinical references: no special prep — unless paired fasting labs ordered |
| Assay mismatch | Never tell patients their AMH “went up” comparing different hospital labs |
| Counseling boundary | Nurses teach what AMH measures; prescribers interpret fertility plans |
| obstetric guidelines screening caution | Question routine AMH screening in non-infertile women — clarify indication |
| IVF timing | Rejected send-out specimen can delay stimulation — track logistics |
| Emotional safety | Low AMH conversations can trigger grief — offer support contacts per unit policy |
AMH in Fertility Clinic Workflow
Diagnostic safety badge: Routine diagnostic test — standard identification, preparation, and result-follow-up checks still apply, with high counseling stakes in fertility care.
Check-before-test protocol
- Identity + indication + correct serum tube
- Screen for assay interferents per laboratory list
- Explain venipuncture and realistic expectations
- Collect, label, centrifuge/transport per send-out policy
- Document teaching and pending result follow-up appointment
Critical teach-back questions
- “Can you tell me why your clinician ordered this hormone test today?”
- “What questions will you ask the fertility or gynecology team when results return?”
- “What symptoms or emotional concerns should you report before your follow-up visit?”
Care coordination: reproductive endocrinology, gynecology, laboratory, phlebotomy, pediatric endocrinology (for pediatric indications), oncology (for tumor monitoring), behavioral health, and social work per institutional protocol.
AMH Pre-test Quick Checklist
- Is there a valid clinical indication, especially if the patient is not being evaluated for infertility?
- Will this result use the same assay and reference interval as prior AMH values?
- Did I collect quality serum and avoid hemolysis?
- Am I avoiding pregnancy outcome predictions at the bedside?
- Who reviews results and counsels the patient — and is follow-up scheduled?
Why Anti-Müllerian Hormone (AMH) is Ordered
AMH is ordered when clinicians need information about ovarian follicle pool size, stimulation planning, or selected reproductive and pediatric conditions.
| Clinical Indication | What the Test Answers | Nursing Rationale |
|---|---|---|
| Female infertility evaluation and IVF planning | What is the ovarian reserve and expected response to stimulation? | Helps estimate follicle pool and guide gonadotropin dosing discussions; higher AMH may predict more retrievable oocytes while very low AMH suggests diminished reserve per specialist protocols. |
| Suspected polycystic ovary syndrome (PCOS) | Is AMH elevated in the context of clinical PCOS features? | Elevated AMH may support PCOS assessment because many small follicles produce more AMH, but AMH alone cannot diagnose PCOS — Rotterdam criteria and clinical findings are required. |
| Menopause or primary ovarian insufficiency assessment | Is ovarian reserve severely reduced or absent? | Low or undetectable AMH may occur near menopause or with primary ovarian insufficiency; AMH cannot predict exact timing of menopause. |
| Pediatric disorders of sex development or undescended testes | Is functioning testicular tissue present? | In infants and children, measurable AMH may indicate testicular tissue; interpretation requires specialist evaluation with chromosome studies and imaging. |
Contraindications and Precautions
There is no absolute laboratory contraindication to venipuncture. Nurses focus on appropriate indication, specimen quality, and avoiding misinterpretation of results.
- Pediatric patient with ambiguous genitalia or suspected anorchia — results must reach pediatric endocrinology or specialist team promptly per protocol.
- Known AMH-secreting ovarian granulosa cell tumor on monitoring — rising AMH may suggest recurrence; escalate to oncology per prescriber plan.
- Patient expresses acute suicidal ideation or severe distress after fertility counseling — activate behavioral health or emergency response per facility policy.
- Assay interference: high-dose biotin or specific fertility drugs may affect some platforms per laboratory manufacturer cautions — verify recent exposures.
- Gross hemolysis may lead to specimen rejection on some analyzers — obtain clean venous sample.
- Ordering AMH for routine fertility prediction in women without infertility is not supported by obstetric guidelines — clarify indication if counseling-only order appears inappropriate.
- Critically distressed patient after unexpected very low AMH in active IVF cycle — notify prescriber and offer immediate support resources per policy.
- Rising AMH during surveillance for granulosa cell tumor when treatment response expected — notify oncology prescriber.
- Specimen rejected (hemolyzed, insufficient volume, wrong tube) when time-sensitive IVF planning depends on result — notify laboratory and prescriber for repeat draw.
Patient Preparation
No special patient preparation is usually required for AMH venipuncture. Preparation focuses on correct identification, indication, and laboratory collection requirements.
Pre-test checksReview recent gonadotropins, GnRH agonists/antagonists, hormonal contraception, and high-dose biotin. Some assays list interference from fertility drugs such as cetrorelix, progesterone preparations, or follistatin per manufacturer labeling — alert the laboratory if the patient received these products within 1–2 weeks when required by local policy.
Performance — nursing procedure guide
This page is a Tests & Diagnostics guide for Anti-Müllerian Hormone (AMH). It emphasizes why the test is ordered, how to interpret results, when to escalate, and preparation factors that affect validity — not step-by-step performance technique (those live under Nursing Procedures when available).
Step-by-step technique, supplies, infection prevention, and immediate post-procedure monitoring for this test are covered in:
Use the Patient preparation, Results and interpretation, and Nursing responsibilities sections on this page for order verification, pre-analytic checks, result follow-up, critical-value escalation, and documentation.
Result follow-up at a glance
Nursing workflow on this page — from order to safe action on results:
Results and Interpretation
AMH is reported in mass units such as ng/mL (assay-specific). Interpret using the reporting laboratory’s age- and sex-specific reference interval on the same assay method — do not apply ranges from other hospitals or internet charts.
Reference ranges, critical values, and protocols may vary by laboratory, institution, patient population, and testing method. Always follow local policy and the reporting laboratory’s reference range.
| Result | Range / Finding | Clinical Meaning | Nursing Action |
|---|---|---|---|
| Within reference interval | Within reporting laboratory age- and sex-specific reference interval for the assay used | Ovarian reserve appropriate for age and clinical context (interpretation by prescriber) | Document result; reinforce that normal AMH does not guarantee pregnancy; schedule counseling as ordered |
| Borderline / near reference limit | Near lower or upper limit of laboratory age-specific interval | May warrant repeat testing, correlation with antral follicle count, or additional hormones per specialist | Notify prescriber per protocol; avoid definitive fertility predictions at the bedside |
| High / above reference interval | Above laboratory upper limit for age/sex | May reflect PCOS pattern, high ovarian reserve, or tumor marker context — depends on indication | Route to gynecology/reproductive endocrinology; discuss ovarian hyperstimulation risk if IVF planned |
| Low / below reference interval | Below laboratory lower limit for age | May reflect diminished ovarian reserve, menopausal range, or primary ovarian insufficiency | Support prescriber counseling; monitor emotional response; expedite specialist appointment if ordered |
Critical Contexts, Result Limits and Escalation
AMH is not typically reported as a hospital critical-value analyte like potassium or troponin. Escalation is driven by clinical context — pediatric disorders of sex development, oncology surveillance, rejected specimens delaying IVF, or patient safety concerns after result disclosure.
| Critical Finding | Threshold / Value | Immediate Action |
|---|---|---|
| Undetectable or menopausal-range AMH in young patient with amenorrhea | Below age-expected interval with symptoms of estrogen deficiency | Notify prescriber; support assessment for primary ovarian insufficiency per protocol |
| Markedly elevated AMH during known granulosa cell tumor surveillance | Rising trend compared with prior assay on same method | Notify oncology prescriber according to tumor surveillance protocol |
| Rejected or hemolyzed specimen before time-sensitive IVF planning | No valid result available when stimulation decision pending | Arrange repeat collection immediately; notify fertility team to evaluate outcomes of cycle timing |
Stop routine workflow and escalate according to facility policy when pediatric AMH results require urgent specialist interpretation, when oncology monitoring shows concerning trends, when specimens are unusable before critical treatment decisions, or when the patient has acute behavioral health needs after result discussion.
Factors Affecting Results
AMH variability is driven by age, assay platform, and pre-analytic factors more than cycle day in many patients — but interference and mis-counseling remain common nursing concerns.
- Apparent ‘good reserve’ in older patient — AMH may be misleadingly mid-range while egg quality declines with age
- Elevated AMH interpreted as PCOS diagnosis without clinical criteria
- Comparing AMH to a friend’s result from a different laboratory assay
- Reassuring single AMH in woman without infertility — routine predictive use is not supported per obstetric guidelines
- Low AMH interpreted as impossible pregnancy — spontaneous conception may still occur in some patients
- Specimen hemolysis or wrong tube leading to falsely low or rejected results
- Assay method and laboratory (values not interchangeable between kits)
- Age and sex of patient
- Recent fertility medications, biotin, or hemolysis per laboratory cautions
, AMH estimates ovarian reserve but does not assess egg quality or predict whether a person will become pregnant. It cannot diagnose PCOS alone, cannot predict time to menopause, and obstetric guidelines advises against routine use for fertility counseling in women without infertility. Immunoassays are not standardized — always use the reporting laboratory reference interval.
Nursing Responsibilities
Nursing care emphasizes accurate serum collection, appropriate counseling boundaries, emotional support in fertility settings, and timely communication with reproductive specialists.
Before the TestDocumentation
Documentation should support safe specimen handling and clear communication about pending fertility decisions.
“AMH serum collected 0842 from right antecubital vein; serum gel tube; patient tolerated well with brief vasovagal lightheadedness resolved with supine positioning. Specimen labeled and sent to reference lab per protocol. Patient taught that fertility physician will discuss results at IVF intake visit Thursday. Denies high-dose biotin; last menstrual period day 3 documented per order.”
- Date, time, site, collector, and tube type
- Indication and cycle day if ordered
- Interfering medications or biotin noted
- Transport/laboratory receipt and pending status
- Patient tolerance and complications
- Teaching provided and follow-up appointment
Patient and Family Education
Use clear, non-judgmental language in fertility and gynecology settings; avoid guaranteeing outcomes.
Anti-Müllerian Hormone (AMH) NCLEX practice questions
Practice NCLEX-style clinical judgment focused on Anti-Müllerian Hormone (AMH) safety and nursing judgment. Use the case tabs (orders, results, assessment, nursing notes), then answer six Next Gen–style items and evaluate outcomes with the answer key.
Select a tab to view orders, results, assessment, and nursing note details for this case.
- Order: AMH — pre-IVF ovarian reserve assessment
- Indication: Primary infertility; planned antagonist IVF cycle
- Timing: AMH drawn today; stimulation start planned in 5 days
- Related orders: Pelvic ultrasound antral follicle count; TSH; prolactin pending
- Result: AMH 0.4 ng/mL (below laboratory age-specific interval); prior year 0.9 ng/mL on same assay
- Trend / prior value: Declining AMH over 12 months on same laboratory method
- Pending tests: Reproductive endocrinology telehealth in 48 hours; no stimulation orders yet
- Vital signs: BP 118/72, HR 78, RR 16, SpO₂ 99% on room air, afebrile
- Symptoms: Reports irregular cycles; tearful after prior low AMH discussion; no acute pain
- Focused assessment: Alert, oriented; mild anxiety; no respiratory distress
- Preparation notes: Serum collected in correct tube; hemolysis-free; patient asks nurse if IVF will definitely fail
- Collection events: Specimen accepted by lab; patient given fertility clinic hotline per protocol
- Teaching gaps / safety concerns: Risk of false reassurance or definitive negative counseling; declining AMH trend; emotional distress
Answer key & rationale
Frequently Asked Questions
FAQ
Does the patient need to fast before an AMH blood test?
No. NIH you do not need special preparations for an AMH test unless other paired labs require fasting — follow the ordering clinician’s instructions.
Can AMH predict whether a patient will become pregnant?
No. In practice, AMH reflects ovarian reserve but does not assess egg quality or predict whether someone will get pregnant. obstetric guidelines similarly cautions against using a single AMH level to counsel women without infertility about future fertility.
Can a high AMH diagnose polycystic ovary syndrome (PCOS)?
Not by itself. a high AMH may support PCOS assessment, but AMH alone cannot diagnose PCOS — clinical and laboratory criteria are required.
Why do AMH results differ between laboratories?
Different immunoassay methods and kits produce different values. the reporting laboratory and peer-reviewed sources emphasize that AMH assays are not standardized and results cannot be interchanged between methods — always use the reporting laboratory reference interval.
When should nurses escalate AMH-related concerns?
Escalate when specimens are rejected before time-sensitive IVF decisions, when pediatric results need urgent specialist review, when oncology surveillance shows concerning AMH trends, or when patients have acute distress or self-harm statements — according to facility policy.
Is AMH stable across the menstrual cycle?
In many clinical settings AMH fluctuates less than some other hormones across the cycle, but nursing practice should still follow local laboratory and prescriber instructions for timing when specified.
What tube is used for AMH collection?
Serum is required. the reporting laboratory lists preferred serum gel and acceptable red-top tubes with centrifugation — follow your institution’s laboratory manual.
References
References
-
U.S. National Library of Medicine. Anti-Müllerian Hormone Test. MedlinePlus.https://medlineplus.gov/lab-tests/anti-mullerian-hormone-test/
-
Mayo Clinic Laboratories. Test ID: AMH1 — Antimullerian Hormone, Serum. Mayo Foundation for Medical Education and Research.https://www.mayocliniclabs.com/test-catalog/overview/608824
-
American College of Obstetricians and Gynecologists. The Use of Antimüllerian Hormone in Women Not Seeking Fertility Care. Committee Opinion No. 773.https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2019/04/the-use-of-antimullerian-hormone-in-women-not-seeking-fertility-care
-
Li HWR; Nelson SM. Challenges in Measuring AMH in the Clinical Setting. Front Endocrinol (Lausanne). 2021.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183164/
-
Office on Women’s Health, U.S. Department of Health and Human Services. Polycystic ovary syndrome. WomensHealth.gov.https://www.womenshealth.gov/a-z-topics/polycystic-ovary-syndrome
-
National Cancer Institute. NCI Dictionary of Cancer Terms: Ovarian reserve. NIH.https://www.cancer.gov/publications/dictionaries/cancer-terms/def/ovarian-reserve
-
American College of Obstetricians and Gynecologists. Anticipatory Counseling Regarding Ovarian-Factor Fertility Decline. Committee Statement. 2025.https://www.acog.org/clinical/clinical-guidance/committee-statement/articles/2025/11/anticipatory-counseling-regarding-ovarian-factor-fertility-decline
-
Josso N; Rey RA. What Does AMH Tell Us in Pediatric Disorders of Sex Development?. Front Endocrinol (Lausanne). 2020.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506080/
Editorial Standards & Medical Review
About the author: Sid A. Abdala Balal, RN, writes evidence-based nursing education focused on diagnostic safety, clinical interpretation, and bedside nursing judgment.
Medical review: This guide is reviewed by Dr. Adam Sayedi, MD, for clinical accuracy, diagnostic safety, and alignment with current standards for Anti-Müllerian Hormone (AMH).
Policies: Medical Review Process · Editorial Policy · Correction Policy